Search - tctmd.com

Displaying 661 - 680 of 899

Sort: Relevancy | Date

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

L.A. McKeown

November 15, 2018

News Conference News AHA 2018

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

Caitlin E. Cox

November 13, 2018

Presentation AHA 2018

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial

Presenter: Sotirios Tsimikas

November 11, 2018

News Conference News AHA 2018

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Shelley Wood

November 11, 2018

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Conference News AHA 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

Todd Neale

November 10, 2018

News Conference News AHA 2018

VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer

Shelley Wood

November 10, 2018

News Conference News AHA 2018

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

Michael O'Riordan

November 10, 2018

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

News Daily News

Statins Provide No Clinical Benefit When Coronary Calcium Is Zero, Study Shows

Michael O'Riordan

November 06, 2018

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Shelley Wood

November 05, 2018

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2018

Shelley Wood

October 31, 2018

News Daily News

Study Questions Role of BP Meds in Patients With Hypertension but No Other CVD Risk Factors

L.A. McKeown

October 30, 2018

News Daily News

Higher Fitness Again Tied to a Lower Risk of Death, Including CVD Mortality

Michael O'Riordan

October 30, 2018

News Daily News

Final Phase III Bempedoic Acid Trial Proves Positive for LDL-Lowering

Shelley Wood

October 29, 2018

News Daily News

Benefit-Based Approach to Statins Pinpoints One in Six Patients Eligible for Therapy

Michael O'Riordan

October 25, 2018

News Daily News

CAC Scoring Is Predictive of Risk Across Races and Ethnicities

L.A. McKeown

October 16, 2018

News Daily News

Elevated Lp(a), Even in Statin-Treated Patients, Linked With Higher CVD Risks

Michael O'Riordan

October 15, 2018

News Daily News

Statin Benefits: Yes for CVD but No for Everything Else, Says New Review

Michael O'Riordan

October 08, 2018

Advertisement

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Statins Provide No Clinical Benefit When Coronary Calcium Is Zero, Study Shows

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

TCTMD’s Top 10 Most Popular Stories for October 2018

Study Questions Role of BP Meds in Patients With Hypertension but No Other CVD Risk Factors

Higher Fitness Again Tied to a Lower Risk of Death, Including CVD Mortality

Final Phase III Bempedoic Acid Trial Proves Positive for LDL-Lowering

Benefit-Based Approach to Statins Pinpoints One in Six Patients Eligible for Therapy

CAC Scoring Is Predictive of Risk Across Races and Ethnicities

Elevated Lp(a), Even in Statin-Treated Patients, Linked With Higher CVD Risks

Statin Benefits: Yes for CVD but No for Everything Else, Says New Review

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content